PROSTATE ADENOCARCINOMA

This study tested a combination of three treatments for men with prostate cancer that had spread to a few spots in the body. The treatments included a radioactive drug that targets bone tumors, hormone therapy to lower testosterone, and precise radiation to kill cancer cells. The…

This study tests whether using a genetic test to personalize hormone therapy can improve outcomes for men with high-risk prostate cancer. For those with a low genetic risk, a shorter course of hormone therapy (12 months instead of 24) is compared to standard care. For those with …

This study looks at men whose prostate cancer has returned after surgery or radiation. It compares standard hormone therapy (which lowers testosterone) to the same therapy plus abiraterone and prednisone, which further block testosterone production. The goal is to see if the comb…

This study tests whether a very low dose of apalutamide, a drug that blocks testosterone, can lower PSA levels in men with early-stage prostate cancer who are about to have their prostate removed. About 34 men will take the drug for 3-4 weeks before surgery. If PSA drops enough, …

This study tests a combination of three drugs (abiraterone, prednisone, and apalutamide) in 60 men with prostate cancer that has spread but hasn't yet been treated with hormone therapy. The goal is to see how long men can stay on treatment and how well it controls the cancer. Par…

This study tests whether giving a higher dose of radiation to the exact spot where prostate cancer has returned (seen on an MRI) can better lower PSA levels in men who have already had their prostate removed. 37 men with a rising PSA after surgery are participating. The goal is t…

This early-phase trial tests the safety and best dose of a radioactive drug (177Lu-rhPSMA-10.1) given after targeted radiation therapy in men whose prostate cancer has returned after prostate removal surgery. The study involves 6 participants and uses a special scan (PSMA PET) to…

This study tests a treatment plan for men with aggressive prostate cancer that combines hormone therapy with two types of radiation: external beam radiation and an internal implant (brachytherapy). The goal is to see if this approach causes fewer side effects while still controll…

This study looks at a type of radiation therapy called high-dose brachytherapy for men with prostate cancer that hasn't spread. Doctors place tiny radioactive sources directly into the prostate to kill cancer cells. The goal is to control the disease while reducing side effects. …

This study tests whether combining surgery and radiation can help men whose prostate cancer has returned and spread to a few spots in the body. Twenty participants will receive targeted treatments to remove or destroy these cancer spots. The main goal is to see if this approach c…

This study tests whether a combination of two drugs (cabozantinib and atezolizumab) works better than standard hormone therapy for men with advanced prostate cancer that has stopped responding to hormone treatment. About 575 men who have already tried one hormone therapy will be …

This study tests whether a combination of three drugs (enteric-coated aspirin, rintatolimod, and interferon-alpha 2b) can boost the immune system's ability to fight prostate cancer when given before surgery. About 12 men with early-stage prostate cancer who are scheduled for pros…

This study uses a genetic test (Decipher score) to decide the best treatment for men with a certain type of prostate cancer. For men with a low-risk gene score, the study tests if radiation alone works as well as radiation plus hormone therapy, potentially avoiding hormone side e…

This study tested whether taking the hormone therapy drug apalutamide for 6 months before prostate removal surgery could reduce signs of aggressive cancer that often lead to radiation therapy afterward. It involved 45 men with intermediate-risk prostate cancer. The goal was to se…

This early-phase study tests whether giving higher doses of radiation to the prostate in fewer sessions is safe for men with intermediate- to high-risk prostate cancer. The treatment also targets nearby lymph nodes. The main goal is to find a schedule that limits severe side effe…

This study tests whether adding the drug relugolix to standard radiation therapy can slow the spread of prostate cancer that has spread to a few other parts of the body. Relugolix lowers testosterone, which can help stop cancer growth. About 194 men with this type of prostate can…

This study tested whether adding enzalutamide to standard hormone therapy and chemotherapy could better control metastatic prostate cancer. Forty men with hormone-sensitive prostate cancer that had spread took part. The goal was to see if the triple combination was safe and more …

This study tests whether white button mushroom supplements can lower PSA levels in men with prostate cancer that has returned or is low-risk and not yet treated. About 133 participants take the supplement or follow standard monitoring. The goal is to see if the mushrooms affect P…

This study tests whether a daily dose of green tea catechins (a natural compound) can prevent low- to intermediate-risk prostate cancer from getting worse in men who are not receiving immediate treatment. Over two years, 115 men on active surveillance will receive either the gree…

This study tests a combination of hormone therapy, chemotherapy (docetaxel), and an immunotherapy drug (nivolumab) in 60 men with metastatic hormone-sensitive prostate cancer that has spread widely. The goal is to see if this triple approach can lower PSA levels more effectively.…

This study tests whether combining two drugs—golimumab (which reduces inflammation) and apalutamide (which blocks male hormones)—can shrink or slow advanced prostate cancer that no longer responds to standard hormone therapy. Eight men with metastatic castration-resistant prostat…

This early-phase study tests whether placing bicalutamide implants directly into the prostate can replace standard hormone therapy (ADT) in men with localized prostate cancer who also receive radiation. About 20 participants will be enrolled. The goal is to see if this targeted a…

This study is testing whether a shorter, more intense course of radiation has fewer side effects for men whose prostate cancer has returned and spread to a few lymph nodes. It compares two radiation methods: proton beam therapy and standard IMRT. The main goal is to see which app…

This study tests a special PET scan called 68Ga-PSMA-11 to see if it can find prostate cancer more clearly than standard scans. About 141 men with prostate cancer that has come back or spread will get this scan. The goal is to see if the scan changes how doctors plan treatment, s…

This study tests a new 3D MRI technique to see if it can find prostate cancer better than standard MRI, without needing a special coil inside the body. About 33 men with untreated, intermediate- or high-risk prostate cancer will be scanned before surgery. The goal is to improve h…

This study is testing a special contrast agent called hyperpolarized 13-C pyruvate to improve MRI scans for prostate cancer. The goal is to see if this technique can find tumors that standard MRIs might miss. About 130 men with prostate cancer will take part. The results could le…

This study tests whether adding furosemide (a diuretic or "water pill") to a special PET/CT scan can reduce bladder radioactivity and improve detection of recurrent prostate cancer in 20 men whose PSA levels rose after prostate removal. Participants receive two scans—one with and…

This study tests a new software that combines MRI and ultrasound images in real time to help doctors more accurately detect and locate aggressive prostate cancer during biopsy. About 100 men scheduled for a standard prostate biopsy will take part. The goal is to improve early dia…

This study compares two types of image-guided radiation therapy for prostate cancer: one using CT scans and the other using MRI scans. The goal is to see if MRI guidance reduces short-term urinary and bowel side effects. About 179 men with localized prostate cancer are participat…

This study is for men with prostate cancer that has spread and is no longer responding to hormone therapy. Researchers collect tissue, blood, and urine samples to study gene changes and look for biomarkers. The goal is to better understand how the cancer behaves and how patients …

This study looks at whether a DNA-based biomarker can help predict long-term urinary side effects from radiation therapy in men with prostate cancer. About 208 patients will have their DNA tested and both they and their doctors will see the results. The goal is to see if knowing …

This study looks at whether giving hormone therapy to men whose prostate cancer has returned can make cancer cells more visible on a special PET scan. About 9 men will take a standard hormone pill for a few weeks and then get a scan to see if new spots light up. The goal is to le…

This study tested whether men with intermediate-risk prostate cancer could follow a Mediterranean diet before their surgery. The goal was to see if this approach is practical and well-tolerated. Twelve participants were enrolled, and researchers will use the results to understand…

This study looks at whether a home-based treadmill walking program can change certain markers of prostate cancer progression in men with low-risk disease who are not receiving active treatment. About 36 men on active surveillance will either follow a prescribed exercise plan or c…

This study tests whether a special type of PET scan, called PSMA PET, can track prostate cancer more accurately than usual scans like CT or bone scans. About 58 men with progressive or newly diagnosed prostate cancer will get PSMA PET scans over time. The goal is to see if change…